

Expanding and Bridging Medical & Economic Sociology

Donald W. Light ¹

Expanding Economic Sociology: Rationing, Organized Voice, Informal Economic Behaviors, Compassionate Charity and Care as non-rational motives

Rationing:

“A Sociological Perspective on Rationing: Power, Rhetoric and Situated Practices.” (with David Hughes) Sociology of Health and Illness 2001;23: 551-69.

Special issue on rationing, Sociology of Health and Illness 2001;23. Edited with David Hughes.

Organized Voice

“No Exit and the Organization of Voice in Biotechnology and Pharmaceuticals,” (with R Castellblanch, P Arrendondo, D. Socolar) Journal of Politics, Policy and Law 2003; 28: 473-507. (the sociology of “voice” in *Exit, Voice and Loyalty*)

Informal Economic Behavior

“From Migrant Enclaves to Mainstream: Reconceptualizing Informal Economic Behavior.” Theory and Society 2004: 33 (6): 703-37.

Altruistic Behavior

“Toward an economic sociology of compassion, charity, and caring.” Presentation at the American Sociological Association, Economic Sociology Section, August 11, 2006, Montreal.

The Theory of Countervailing Powers: Professions, Markets and States

Light, DW. “Health Care Professions, Markets, and Countervailing Powers.” Ch 14 in Handbook of Medical Sociology 6th Edition. Chloe Bird, Peter Conrad, Allen Fremont & Stefan Timmermans, Eds., 2010.

“Ironies of Success: A New History of the Current Health Care ‘System’” Journal of Health and Social Behavior 2004; 45 (special issue): 1-24

“The Medical Profession and Organizational Change: From Professional Dominance to Countervailing Power.” Pp. 201-16 in the Handbook of Medical Sociology – 5th edition. C. Bird, P. Conrad, A. Fremont, eds. Prentice-Hall, 2000.

“The Rhetorics and Realities of Community Health Care: Limits of Countervailing Powers to Meet the Health Care Needs of the 21st Century.” Journal of Health Politics, Policy and Law 1997; 22:105-45.

¹ Professor, University of Medicine & Dentistry of New Jersey. Visiting researcher, Center for Migration & Development, Princeton University. Fellow, Center for Bioethics, University of Pennsylvania. Lokey visiting professor, Stanford University 2009-11.

Hafferty FW, Light D. "Professional Dynamics and the Changing Nature of Medical Work." Journal of Health and Social Behavior 1995 (extra issue):132-53.

"Countervailing Powers: A Framework for Professions in Transition." In Health Professions and the State in Europe, edited by T. Johnson, G. Larkin & M. Saks. London: Routledge, 1995: 25-41.

"Countervailing power: the changing character of the medical profession in the United States." Pp 69-79 in The Changing Medical Profession: An International Perspective, F.W. Hafferty & J.B. McKinlay, eds. New York: Oxford University Press, 1994. several reprints

"Turf Battles and the Theory of Professional Dominance." Research in the Sociology of Health Care, 1988;7: 203-225.

Distributive Justice

"The Practice and Ethics of Risk-Rated Health Insurance." Journal of the American Medical Association 1992;267: 2503-2508.

"Life, death, and the insurance companies." New England Journal of Medicine 1994;330:498-499.

Daniels N, Light D, Caplan R. Benchmarks of Fairness for Health Care Reform. Oxford University Press, 1996.

"Keeping Competition Fair for Health Insurance: How the Irish Beat Back Risk-Rated Policies." American Journal of Public Health 1998;88:745-8.

"Fostering a Justice-based Health Care System." Contemporary Sociology 2000;29 (1): 62-74.

Caplan R, Light D, Daniels N. "Benchmarks of Fairness: A Moral Framework for Assessing Equity." International Journal of Health Services 2000; 29:853-69.

Menzel, Paul and D W Light. "A conservative case for universal access to health care." The Hastings Center Report July/Aug 2006: 3-11.

Light DW. "Globalizing restricted and segmented markets: challenges to theory and values in economic sociology." Annals of the American Academy of Political and Social Science Mar 2007, Vol 610: 232-45. <http://ann.sagepub.com/content/610/1/232.full.pdf+html>

Light DW. "Fair Pricing and Access of Medicines for the Poor." Ch 47 in The Penn Center Guide to Bioethics. Eds: V. Ravitsky, A. Feister, A. L. Caplan. Springer 2009.

Outterson K, Light DW. "Global Pharmaceutical Markets." Forthcoming in A Companion to Bioethics. Eds: P. Singer, Blackwell, 2010 (forthcoming).

Sociology of Immigration and Health Care

Portes A, Light D, Fernandez-Kelly P. "The U.S. health system and immigration: an institutional interpretation." Sociological Forum 2009; 24(3): 487-514

Portes A, Fernandez-Kelly P, Light D., “Life on the edge: immigrants confront the American health system.” Ethnic and Racial Studies 2012; 35:3-22.

Light, DW. “Categorical Inequalities, Institutional Ambivalence, and Permanently Failing Social Institutions: Immigrants and Barriers to American Health Care.” Ethnic and Racial Studies 2012; 35:23-39.

Light D. “Institutional ambivalence and permanently failing health care: access by immigrants and the categorically unequal in the nation and New Jersey. Working Paper 09-01, Center for Migration and Development, Princeton University. 2009.
<http://cmd.princeton.edu/papers.shtml>

Light D. “Toward an economic sociology of compassionate charity and care.” Working Paper 07-02, Center for Migration and Development, Princeton University. 2007.
<http://cmd.princeton.edu/papers.shtml>

Light, DW. From Migrant Enclaves to Mainstream: Reconceptualizing Informal Economic Behavior. Theory and Society 2004; 33 (6): 703-37

Demythologizing Pharmaceutical Policy Claims (see www.pharmamyths.net)

“Drugs are Safe and Effective, and Life-saving”

The Risks of Prescription Drugs, Columbia University Press, 2010.

“Bearing the risks of prescription drugs.” Chapter 1 of The Risks of Prescription Drugs.

“The FDA: inadequate protection from drug disasters and serious risks.” Chapter 2 of The Risks of Prescription Drugs.

“Medicaments dangereux: les Européens tenus dans l’ignorance.” Prescrire 2008 (July) 28 (297): 553

Brody, H, Light, DW. “The inverse benefit law: how drug marketing undermines public safety and public health.” American Journal of Public Health 2011; 101:399-404.

“Europeans are Free Riders on Americans, who pay their R&D costs”

Light, DW. “Global Drug Discovery: Europe is Ahead,” Health Affairs – web exclusive 2009 (25 Aug): w969-77. <http://content.healthaffairs.org/cgi/reprint/hlthaff.28.5.w969v1>

Global press coverage and

The Lancet editorial, “Dispelling myths about drug research.” 1 Sept 2009, vol 374:758.

Reported in Nature 2 Sept 09.

The Economist analysis: “Developing new drugs.” 27 Aug 2009

SCRIP analysis: Faraz Kermani, “Europe reaps the benefits of being R&D underdog.”

BBC Radio 4 feature: U.S. Health Reforms: Beware of Side Effects, with Justin Webb, 11 Oct 09

13:30-14:00. <http://www.bbc.co.uk/programmes/b00n8ss0>

Invited Health Affairs Blog comment: <http://healthaffairs.org/blog/2009/11/24/drug-prices-and-health-reform/>

Stolk, P & Light. “Did the U.S. eclipse European pharmaceutical research productivity? An analysis of major reports as searchlights in the fog.” Report for the Escher Project, University of Utrecht, Dec. 2008.

Light DW, Lexchin J. “Will lower drug prices jeopardize drug research? A policy fact sheet.” American Journal of Bioethics 2004;4(1): w3-w6.

Light DW and Lexchin, J. “Foreign free riders and the high price of U.S. drugs.” BMJ 2005; 331: 958-60. <http://www.bmj.com/content/331/7522/958.full.pdf+html>

“It costs us \$1-2 billion to bring a new drug to market.”

Light, DW. and R Warburton, “Demythologizing the high costs of pharmaceutical research,” Biosocietes 2011 (Win): 1-17.

Light, DW. “Misleading Congress on Drug Development.” Journal of Health Politics, Policy and Law 2007; 32: 895-913. <http://jhpl.dukejournals.org/cgi/reprint/32/5/895>

Light D. W. “Basic research funds to discover important new drugs: Who contributes how much?” Ch. 3 in Monitoring the Financial Flows for Health Research Behind the Global Numbers, Mary Anne Burke and Andrew de Francisco, eds. Geneva: The Global Forum for Health Research, 2006.

Light, DW and Warburton R. “Extraordinary Claims Require Extraordinary Evidence.” Journal of Health Economics 2005; 24:1030-33.

Light DW and Warburton R. “Setting the Record Straight.” Journal of Health Economics 2005; 24:1045-48.

High drug prices reflect huge R&D costs. -Or their value.

Light DW. “Pricing Pharmaceutical Drugs in the USA.” Chapter 6 in The Disorientation of Medicine and Medical Research, A. Thompson & NJ Temple, eds.. Kluwer, 2007.

Light DW. “The myth of value pricing – so far.” Health Affairs Blog 2007 (20 Feb) <http://healthaffairs.org/blog/2007/02/20/biotech-the-myth-of-value-based-pricing-%e2%80%93-so-far/>

“Advanced Market Commitments are the best way to buy vaccines to save millions of poor”

Light DW. Making Practical Markets for Vaccines. Public Library of Science – Medicine 2005, 2(10): e271-74. <http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0020271>

Light DW. “Advanced purchase commitments: moral and practical problems,” in The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing Policies, Patricia Illingworth, Udo Schullenk, and Julian Clare Cohen, eds., London: Pluto Press 2006: 137-141.

Light, D. W. “Is the G8 putting profits before the world’s poorest children?” The Lancet 2007; 370: 297-98. <http://download.thelancet.com/pdfs/journals/lancet/PIIS014067361060267X.pdf?id=e16241398b8eb460:171b4d28:12c2c7b7de9:20b61289241790636>

Light DW. “Missing the real issue about the pneumo AMC.” Development Today 2008

(June 11) XVIII, No. 8, p 11.

Light, DW. Evidence prepared for Parliament (UK), All-Party Parliamentary Group on pneumococcal disease prevention in the developing world. April 2008.

Light, DW. Advanced Market Commitments: Current Realities and Alternate Approaches. Amsterdam: HAI-Europe and Medico International, 2009.
<http://www.haiweb.org/31032009/27%20Mar%202009%20AMC%20Current%20Realities%20&%20Alternate%20Approaches%20FINAL.pdf>

Light DW, JK Andrus, R Warburton. "Estimated research and development costs of rotavirus vaccines." Vaccine 2009; 27: 6627-33.
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TD4-4WY4T5P-4&_user=145269&_coverDate=11%2F05%2F2009&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&_view=c&_searchStrId=1574025339&_runOrigin=google&_acct=C000012078&_version=1&_urlVersion=0&_userid=145269&md5=4be27d2a9a2dff931b4e3a22ea3c683a&searchtype=a

Consumer protest over prices / Containing costs fairly / Slanting science & journals

Light D, Castellblanch R, Arrendondo P, Socolar D. "No Exit and the Organization of Voice in Biotechnology and Pharmaceuticals," Journal of Politics, Policy and Law 2003; 28: 473-507. <http://jhppl.dukejournals.org/cgi/reprint/28/2-3/473>

"A Framework for Containing Costs Fairly." (with T. Walley) Pp 346-58 in Regulating Pharmaceuticals in Europe: Containing Costs while Improving Efficiency, Quality and Equity. Mossialos E, Mrazek M, Walley T, eds. Open University Press, 2004.

Lexchin, Joel and D W Light. "Commercial influence and the content of medical journals." BMJ 2006 332:1444-47.
<http://www.bmj.com/content/332/7555/1444.full.pdf+html>

Light, DW. "Struggling for the soul of academic medicine." American Journal of Bioethics 2007; 7(5): 61-63.

Light DW and Warburton, R. "Ethical Standards for Healthcare Journal Editors: A Case Report and Recommendations." Harvard Health Policy Review 2008; 9(1): 58-67.

http://www.hcs.harvard.edu/~hhpr/currentissue/058-067%20In%20Focus_Light,%20Warburton.pdf

Richard Smith, MD (past editor BMJ) "A ripping yarn of editorial misconduct." BMJ group blogs.

<http://blogs.bmj.com/bmj/2008/10/21/richard-smith-a-ripping-yarn-of-editorial-misconduct/>

Brendan Borrell, "Pharma Critics censored?" The New Scientist 21 Oct 2008. <http://www.the-scientist.com/news/print/55101/>

June Wu, "Journal Integrity Questioned" Harvard Crimson

<http://www.thecrimson.com/article/2008/10/10/journal-integrity-questioned-span-stylefont-weight-boldsee/>

Ed Silverman, "The case of the disappearing journal." Pharmalot.com

<http://www.pharmalot.com/2008/10/the-case-of-the-disappearing-journal-article/>

Merrill Goozner: "Where's Harvard's missing Health Policy Journal?"

<http://www.gooznews.com/archives/001223.html>

Sarah Arquist, "Researchers question publishing ethics of leading economics journal."

http://www.thehealthcareblog.com/the_health_care_blog/2008/10/bad-light-falls.html

Pharmagossip, "Harvard Health Policy Review: the case of the missing article."

<http://pharmagossip.blogspot.com/2008/10/harvard-health-policy-review-case-of.html>

The Social Construction of Health Care Markets & Managed Care

A. Comparative frames: stakeholder values and countervailing powers

“Health Care Markets: Theory and Practice.” International Encyclopedia of the Social and Behavioral Science, 2002, vol 10, pp 6523-27. Amsterdam: Elsevier.

Social Science and Medicine (special issue on States, Markets and Institutional Adaptation: Comparative Analysis of Competition Policy in Health Care) 58 (2), 2001.

“Comparative Institutional Response to Economic Policy: Managed Competition and Governmentality,” Social Science and Medicine 2001;52(8):1151-66.

"Comparing Health Care Systems: Lessons from East and West Germany." Pp. 429-444 in P. Conrad and R. Kern (eds.) Sociology of Health and Illness: Critical Perspectives, 2nd Edition, New York: St. Martin's Press, 1986.

"Effectiveness and efficiency under competition: the Cochrane test." British Medical Journal 1991;303: 1253-4.

"Embedded Inefficiencies in Health Care." The Lancet 1991;338:102-104.

"Escaping the Traps of Postwar Western Medicine," European Journal of Public Health 1994;3:281-9.

"Health Care Systems and Their Financing." Pp. 355-64 in The New Oxford Medical Companion. Lord Walton, Griff Owen, Philip Rhodes, eds. London: Oxford University Press, 1994.

“The Sociological Character of Markets in Health Care.” Pp. 394-408 in Handbook of Social Studies in Health and Medicine, edited by GL Albrecht, R. Fitzpatrick, and SC Scrimshaw. London: Sage, 2000.

“Sociological Perspectives on Competition in Health Care,” Journal of Health Politics, Policy and Law 2000;25:973-78.

“Cost Containment and the Backdraft of Competition Policies,” International Journal of Health Services 2001;31: 681-708.

B. U.S. Managed Competition and Managed Care

"Corporate Medicine for Profit," Scientific American 1986;225 (6): 38-45. (In Japanese 6/87, Chinese 7/87).

"Managed care: false and real solutions." The Lancet 1994; 344:1197-99.

"*Homo Economicus*: Escaping the Traps of Managed Competition." European Journal of Public Health 1995; 5:145-54.

“Good Managed Care Needs Universal Health Insurance,” Annals of Internal Medicine 1999; 130: 686-9.

Journal of Health & Social Behavior (Special issue on the origins and dynamics of American

health care) 2004; 45 (special issue). Light DW, Bourgeault, I. Eds.

“American health care: inefficient, inequitable, and costly.” In Politics and Policy 4th Ed., James A. Morone, Theodor J. Litman, Leonard S. Robin, eds. Delmar 2008:223-248. (Student version of history of U.S. system.)

“Managed Care: Its Origins and Prospects.” In Perspectives in Medical Sociology, 4th Edition. Phil Brown, ed. (Long Grove, Illinois: Waveland Press): 382-99.

“Historical and comparative reflections on the U.S. national health insurance reforms,” Social Science & Medicine 2011; 72: 129-132.

C. U.K. Managed Care & Markets

Effective Commissioning: Lessons from Purchasing in American Managed Care. London: Office of Health Economics, 1998.

"Observations on the NHS reforms: an American perspective." British Medical Journal 1991;303: 568-570.

"The Radical Experiment: Transforming Britain's National Health System to Interlocking Markets." Journal of Public Health Policy 1992;13: 146-155.

"Equity and Efficiency in Health Care." Social Science & Medicine 1992;35: 465-469.

"Betrayal by the Surgeons." Lancet 1996;347: 812-3.

“Policy Lessons from the British Health Care System.” Pp. 438-499 in Health Care Reform: International Perspectives, edited by F.D. Powell and A.F. Wessen. Sage, 1998.

“Managed Care in a New Key: Britain’s Strategies for the 1990s.” International Journal of Health Services 1998;28:427-44.

“Is NHS Purchasing Serious? An American Perspective.” BMJ 1998;316:217-20.

“From Managed Competition to Managed Cooperation: Theory and Lessons from the British Experience.” The Milbank Quarterly 1997; 75:297-341 (Lead article)

“The real ethics of rationing.” BMJ (British Medical Journal) 1997;315:112-15.

"Managed Competition: Theory and Lessons from the British Experience." Pp. 322-56 in Competitive Managed Care: The Emerging Health Care System. Edited by John Wilkerson, Kelly Devers and Ruth Given. San Francisco: Jossey-Bass, 1997.

“How Waiting Lists Work and their Hidden Agenda,” Consumer Policy Review (UK) 2000;10(4):126-132

“Here We Go Again: Repeating Implementation Errors.” BMJ (British Medical Journal) 1999;319:616-8.

“Managed Competition, Governmentality and Institutional Response in the United Kingdom,” Social Science and Medicine 2001;52(8): 1167-82.

“Making the NHS more like Kaiser Permanente.” (with M. Dixon) BMJ 2004;328:763-5.

“Universal Health Care: Lessons from the British Experience.” American Journal of Public Health 2003; 93: 25-30.

“Will the NHS strategic plan benefit patients?” BMJ 2008; 337:210-12.

Light, DW and Connor, M. “Reflections on commissioning and the English coalition government NHS reforms,” Social Science & Medicine 2011; 72:821-22.

Keen J, Light D, Mays N. Public-Private Relations in Health Care London: The King’s Fund, 2001.

Light D, Blair T (the Prime Minister) Future Challenges for the NHS: An International Perspective on the 50th Anniversary. London: The Nuffield Trust, 1999.